Chimeric antigen receptor-modified T cells for the treatment of solid tumors: defining the challenges and next steps
GL Beatty, M O'Hara - Pharmacology & therapeutics, 2016 - Elsevier
GL Beatty, M O'Hara
Pharmacology & therapeutics, 2016•ElsevierChimeric antigen receptor (CAR) T cell therapy has shown promise in CD19 expressing
hematologic malignancies, but how to translate this success to solid malignancies remains
elusive. Effective translation of CAR T cells to solid tumors will require an understanding of
potential therapeutic barriers, including factors that regulate CAR T cells expansion,
persistence, trafficking, and fate within tumors. Herein, we describe the current state of CAR
T cells in solid tumors; define key barriers to CAR T cell efficacy and mechanisms underlying …
hematologic malignancies, but how to translate this success to solid malignancies remains
elusive. Effective translation of CAR T cells to solid tumors will require an understanding of
potential therapeutic barriers, including factors that regulate CAR T cells expansion,
persistence, trafficking, and fate within tumors. Herein, we describe the current state of CAR
T cells in solid tumors; define key barriers to CAR T cell efficacy and mechanisms underlying …
Abstract
Chimeric antigen receptor (CAR) T cell therapy has shown promise in CD19 expressing hematologic malignancies, but how to translate this success to solid malignancies remains elusive. Effective translation of CAR T cells to solid tumors will require an understanding of potential therapeutic barriers, including factors that regulate CAR T cells expansion, persistence, trafficking, and fate within tumors. Herein, we describe the current state of CAR T cells in solid tumors; define key barriers to CAR T cell efficacy and mechanisms underlying these barriers, outline potential avenues for overcoming these therapeutic obstacles, and discuss the future of translating CAR T cells for the treatment of patients with solid malignancies.
Elsevier